Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
111-indium-CMD-193
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
111-indium-CMD-193 is a radiolabeled antibody-drug conjugate composed of CMD-193 (a humanized monoclonal antibody targeting the Lewis Y antigen) conjugated to the cytotoxic agent calicheamicin and labeled with the radioisotope indium-111. The radiolabel allows for detection of the drug's biodistribution and tumor localization using gamma scintigraphy. CMD-193 specifically binds to tumors expressing the Lewis Y antigen, delivering both targeted cytotoxicity via calicheamicin and enabling imaging through indium-111. The drug was developed for use in patients with advanced cancers expressing Lewis Y antigen but showed rapid blood clearance and increased hepatic uptake with low tumor accumulation in clinical studies[1][2][5]. Myelosuppression and liver function effects were notable adverse events[5]. Development has been discontinued.
- Other names
- indium In 111-CMD-193indium In 111 hu3S193-calicheamicin conjugate
02
Targets
LeY (Lewis Y antigen)
Beyond the preview
Go deeper on 111-indium-CMD-193.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 111-indium-CMD-193.